MedPath

Tagged News

Yatiri Bio Acquires NGeneBioAI to Strengthen AI-Powered Proteomics Platform for Precision Medicine

AIPrecision Medicine
  • Yatiri Bio has successfully acquired NGeneBioAI, a San Diego-based company specializing in plasma proteomics and AI-powered diagnostics, to strengthen its position in biomarker discovery and translational drug development.
  • The acquisition expands Yatiri Bio's operational capabilities by integrating CLIA- and CAP-certified laboratory infrastructure and enhancing its AI-proteomics platform that uses deep learning to map disease biology.
  • The expanded platform will support biomarker-driven programs across oncology, immunology, and neurodegeneration while strengthening partnerships with biopharma companies seeking companion diagnostics.
  • Yatiri Bio's platform uses deep neural networks to integrate proprietary proteomics, clinical metadata, and functional testing to identify responsive patient populations for clinical candidates.

Taconic and Cyagen Form Strategic Partnership to Expand Access to 16,000+ Genetically Engineered Mouse Models

AIDrug Discovery
  • Taconic Biosciences and Cyagen Biosciences announced a strategic partnership to provide preclinical researchers with streamlined access to Cyagen's library of over 16,000 genetically engineered mouse models.
  • Taconic will serve as the exclusive distributor of Cyagen's animal model library in North America and Europe, combining AI-generated models with world-class production services.
  • The collaboration expands Taconic's existing library from 4,500 to over 20,500 mouse models, including knockout, conditional knockout, and Cre-recombinase expressing models for disease research.
  • The partnership aims to accelerate drug discovery across multiple therapeutic areas including neurodegeneration, rare diseases, immuno-oncology, and metabolic disorders.

OneMedNet Expands Real-World Data Network by 25%, Adding 5 Billion Administrative Records

AIRare Disease
  • OneMedNet Corporation announced a greater than 25% expansion of its proprietary iRWD™ network, adding over 5 billion administrative records to support health economics research and social determinants of health insights.
  • The expanded network now encompasses 1,750+ healthcare system and provider partner sites, covering 34 million patients and 136 million clinical exams across rare diseases, oncology, and cardiology.
  • The expansion positions OneMedNet for significant revenue growth through increased data licensing and enterprise partnerships in the $60 billion real-world evidence industry.

Certara Appoints AI Pioneer Dr. Chris Bouton as CTO to Advance Next-Generation Drug Development Platform

AI
  • Certara has appointed Dr. Christopher Bouton, founder of Vyasa Analytics, as Chief Technology Officer to lead development of an AI-powered model-informed drug development platform.
  • Dr. Bouton will spearhead technology strategy for integrating generative AI and biosimulation technology to accelerate drug discovery and development timelines.
  • The appointment strengthens Certara's position in the competitive biosimulation market, building on Bouton's track record of developing AI solutions including CoAuthor™ for regulatory writing.
  • Certara's next-generation platform aims to increase efficiency in discovering novel therapeutics by combining scientific expertise with advanced AI approaches.

ChatGPT Reduces Clinical Trial Screening Time from 40 Minutes to Under 3 Minutes, But Human Oversight Still Required

AIOncology
  • ChatGPT-4 demonstrated superior performance over ChatGPT-3.5 in screening patients for clinical trials, achieving 84% accuracy with better sensitivity and specificity balance.
  • Screening times were dramatically reduced from over 40 minutes per patient to 1.4-3.0 minutes with GPT-3.5 and 7.9-12.4 minutes with GPT-4, though costs ranged from $0.02-$0.27 per patient.
  • Both AI models showed high specificity but low sensitivity in identifying eligible patients, with GPT-4 having only 16% median sensitivity despite 100% specificity.
  • Researchers concluded that large language models should complement rather than replace manual chart reviews due to difficulties in identifying patients who meet all eligibility criteria.

Protopia AI Secures $1.25M Air Force Contract to Advance Privacy-Preserving AI Technology for Secure Code Development

AI
  • Protopia AI received a $1.25 million Direct-to-Phase II SBIR contract from the U.S. Air Force to demonstrate its Stained Glass Transform technology for secure AI-powered software development.
  • The technology enables Air Force teams to use coding large language models without exposing proprietary codebases in plain text, addressing critical security concerns in AI adoption.
  • This partnership with the Air Force Sustainment Center Software Directorate represents a significant milestone for privacy-preserving AI applications in mission-critical environments.
  • The contract highlights the growing need for dual-use technologies that enable secure generative AI adoption across both military and commercial applications.

Ultromics Secures $55M Series C to Scale AI-Powered Heart Failure Diagnostics Across US Hospitals

AI
  • Ultromics raised $55 million in Series C funding to expand its FDA-cleared EchoGo platform for detecting heart failure with preserved ejection fraction (HFpEF) and cardiac amyloidosis across US hospitals.
  • The AI-powered diagnostic tool improved HFpEF detection by 73.6% compared to traditional methods and has analyzed over 430,000 echocardiograms to date.
  • With Medicare reimbursement secured and partnerships with major health systems including UChicago Medicine and Mayo Clinic, the platform addresses a critical diagnostic gap where up to 64% of heart failure cases go undetected.
  • Heart failure drives over $30 billion in annual US healthcare costs, projected to exceed $70 billion by 2030, highlighting the urgent need for improved diagnostic capabilities.

Fresenius Medical Care Partners with Azenta to Advance Precision Kidney Disease Care Through Genomic Analysis

Precision MedicineAI
  • Frenova, Nephronomics, and GENEWIZ by Azenta Life Sciences have formed a strategic collaboration to advance genomic analysis of Frenova's My Reason® genomics research program.
  • The My Reason® program has registered over 35,000 participants with biospecimens, aiming to reach 50,000 participants over the next two years to build the world's most comprehensive kidney disease database.
  • The collaboration will leverage whole genome sequencing and AI/machine learning models to identify novel disease subtypes, protective genetic variants, and therapeutic targets for cardio-kidney-metabolic diseases.
  • GENEWIZ will provide DNA sequencing technologies and long-term sample storage through Azenta's global biorepository network to extract insights from the genomic and clinical data registry.

Inka Health Partners with OneMedNet to Develop AI-Powered External Control Arms for Cancer Drug Development

AIReal World EvidenceOncology
  • Inka Health has been selected by OneMedNet to lead a data analytics initiative using real-world data to develop external control arms as a faster, more cost-effective alternative to traditional clinical trials.
  • The project will deploy Inka Health's proprietary SynoGraph platform to build and validate an external control arm for the Keynote-189 trial of pembrolizumab in non-small cell lung cancer.
  • This collaboration aims to accelerate market entry for new cancer therapies by offering a more efficient path to generate evidence needed for regulatory and reimbursement approvals.
  • The initiative positions both companies in the rapidly expanding Real-World Evidence market, projected to exceed $4.6 billion globally by 2030.

Topcon Acquires AI-Powered Diabetic Retinopathy Screening Company IRIS to Expand Connected Care Platform

AI
  • Topcon Healthcare acquired Intelligent Retinal Imaging Systems (IRIS), a cloud-based retinal screening technology company, to integrate AI-powered diabetic retinopathy screening into its Healthcare from the Eye initiative.
  • IRIS has enabled over 1.8 million screenings and identified more than 279,000 cases of diabetic retinopathy across 650+ healthcare organizations since its founding in 2012.
  • The acquisition will strengthen Topcon's Harmony platform by adding IRIS's referral and communication capabilities to improve care coordination between primary care and eye care providers.
  • The integration aims to enable early identification of patients at risk of ocular disease during primary care visits and facilitate timely referrals to eye care specialists.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.